CRESCENT BIOPHARMA INC (CBIO)
Health Care · biotechnology · NASDAQ
A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors.
What CRESCENT BIOPHARMA INC does
Crescent Biopharma is a clinical-stage biotechnology company focused on developing oncology therapies. Its strategy centers on the development of CR-001, a PD-1 x VEGF bispecific antibody, alongside a portfolio of antibody-drug conjugates (ADCs) including PD-L1 and ITGB6-targeted candidates. The company aims to combine these therapies to create synergistic treatments for various solid tumors.
Themes: oncology therapeutics, bispecific antibodies, antibody-drug conjugates (ADCs), immuno-oncology, solid tumor treatments
Fundamentals
- Price$17.15 as of 2026-08-21 close
- Market cap$637M as of 2026-08-21
- 1-year return+19.1% 2025-08-21 close $14.40 → 2026-08-21 close $17.15
- P/En/a negative earnings
- Net margin-990.3% as of 2026-08-24
- Gross margin-0.5% as of 2026-08-24
- ROE-100.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+413.7% as of 2026-08-24
- Beta1.28 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How CBIO compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CRESCENT BIOPHARMA INC looks technically
CRESCENT BIOPHARMA INC (CBIO) is trading 12.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 90 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 5 trading days ago. It is 37.4% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 12.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +12.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.71 | $16.71 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.20 | $15.20 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 13.99. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 90 trading days ago — a "golden cross", a bullish long-term signal | 90 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 12.9% above | +12.8% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($14.88 to $18.06) — its "stochastic" reading is 71 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 71.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.41 | $27.41 |
|---|---|---|
| From the 52-week high | it is 37.4% below its 52-week high (its highest price of the past year) | -37.4% |
| Above the 52-week low | it is 96.7% above its 52-week low (its lowest price of the past year) | +96.7% |
| Below the 52-week high | it is 37.4% below its highest point of the past year | 37.4% |
| Since a 20-day breakout | it made a new 20-day high about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $2605.00 (set on 2018-02-15) | $2605.00 |
| Given back of the 52-week move | over the past year its closes ranged ($8.94 to $26.98), and it has given back around half of its rise from last year’s low — 54% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.25 to $15.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 54.5% |
| From the all-time high | it is 99.3% below its all-time high | -99.3% |
| Nearest price level | it is trading 4.1% above a support level at $16.44 — a price it turned at twice since 2025-12-04, most recently on 2026-06-02. Since 2024-08-21 it has 9 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.1% |
| All-time low | its lowest closing price on record is $8.72 (set on 2026-02-09) | $8.72 |
| Above the all-time low | it is 96.7% above its all-time low | +96.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.18 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.18 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.58 and $18.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.58 – $16.35 – $18.12 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
| Stretch from the 200-day average | it is trading 1.7 daily ranges above its 200-day average price (12.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.66× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 7.2% below the previous close 57 sessions ago and has not traded back through the level it left behind at 20.65 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -7.2% |
| Gap filled | a 2.7% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.7 percentage points (the stock gained 3.1% while the market gained 2.3%) | +0.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 18.3 percentage points (the stock lost 15.2% while the market gained 3.1%) | -18.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 36.1 percentage points (the stock gained 47.2% while the market gained 11.1%) | +36.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 1.4 percentage points (the stock gained 19.1% while the market gained 20.5%) | -1.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $16.42 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +4.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-07-14 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $15.93 — a volume-weighted average of daily closes over 29 sessions, not a true tick-by-tick VWAP. | +7.6% |
Price levels it has turned at before
CBIO last closed at $17.15 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.44 | Support | 4.1% below the last close | turned there twice · 2025-12-04 to 2026-06-02 |
| $19.09 | Resistance | 11.3% above the last close | turned there three times · 2024-12-19 to 2026-06-29 |
| $14.81 | Support | 13.6% below the last close | turned there twice · 2026-01-21 to 2026-05-01 |
| $14.00 | Support | 18.4% below the last close | turned there twice · 2025-07-18 to 2026-07-31 |
| $21.55 | Resistance | 25.6% above the last close | turned there twice · 2025-06-25 to 2026-05-15 |
| $28.00 | Resistance | 63.3% above the last close | turned there three times · 2024-11-25 to 2025-05-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $13.99.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$30.60 range $27.00 – $35.00; median $28.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CBIO
- Consensus EPS estimate-$0.57 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no commercial products and a history of operating losses.","Reliance on strategic partnerships, specifically with Kelun-Biotech, for key product development.","Substantial funding requirements to complete clinical trials and potential need for additional capital."]
Insider activity (SEC Form 4)
1 open-market purchase and 7 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($12M) · 7 sells ($1M) — 1 buying, 7 selling insiders
- Last 180 days1 buy ($12M) · 7 sells ($1M) — 1 buying, 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-16. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CBIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
CBIO had 3,465,334 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CBIO had 9.33% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.92 days to cover at the same settlement.
- Reported short interest (shares) 3,465,334
- Short interest (% of shares outstanding) 9.33%
- Prior settlement (shares) 3,743,278
- Reported change -7.43%
- Days to cover (reported) 8.92
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- AstraZeneca (AZN)
- Seagen (Pfizer) (PFE)
- Daiichi Sankyo (DSNKY)
- Gilead Sciences (GILD)
- ImmunoGen (AbbVie) (ABBV)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CBIO vs…
CRESCENT BIOPHARMA INC is found in…
CBIO ranks in…
Frequently asked questions
What does CRESCENT BIOPHARMA INC (CBIO) do?
Crescent Biopharma is a clinical-stage biotechnology company focused on developing oncology therapies. Its strategy centers on the development of CR-001, a PD-1 x VEGF bispecific antibody, alongside a portfolio of antibody-drug conjugates (ADCs) including PD-L1 and ITGB6-targeted candidates. The company aims to combine these therapies to create synergistic treatments for various solid tumors.
What sector is CRESCENT BIOPHARMA INC (CBIO) in?
CRESCENT BIOPHARMA INC (CBIO) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CRESCENT BIOPHARMA INC's (CBIO) competitors?
Notable peers of CRESCENT BIOPHARMA INC (CBIO) include Merck, AstraZeneca, Seagen (Pfizer), Daiichi Sankyo and Gilead Sciences. This peer set is informational only — not financial advice.
Is CRESCENT BIOPHARMA INC (CBIO) overbought or oversold right now?
CRESCENT BIOPHARMA INC (CBIO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CBIO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.